Printer Friendly

New insights into the genetics of congenital neutropenia/Konjenital notropenilere genetik bakys.

Neutropenia is an important condition that brings about a tendency to severe, sometimes life-threatening infections. The cause of neutropenia can be congenital or acquired. Recently, major advances have occurred in the field of molecular genetics concerning congenital neutropenia (CN) that will be addressed in this review. Common causes of CN and related mutations are shown in Tables 1 and 2, respectively [1]. Most of these disorders are inherited in an autosomal recessive trait that increases the number of such patients in countries like Turkey, where consanguineous marriages are frequent.

Congenital neutropenia with defective myelopoiesis

Severe Congenital Neutropenia

Severe congenital neutropenia (SCN) was identified by Kostmann, a Swedish pediatrician, in 1956 as "a new recessive lethal disease in man" (Kostmann syndrome) [2]. However, it has been understood that only one-third of patients inherited the disease as a recessive trait. Therefore, SCN was proposed as a general name of a group of disorders with different inheritance patterns caused by mutations in different genetic loci. The most characteristic clinical finding is recurrent, severe bacterial infections beginning from birth, such as abscesses of perirectal skin or liver, omphalitis, otitis media, and upper and lower respiratory tract infections, caused by common or uncommon bacterial agents [3,4]. Orodental problems, such as gingival hyperplasia, which may lead to premature loss of permanent teeth, and aphthous stomatitis are frequently seen among patients with SCN. Splenomegaly has been observed in 20% of patients at first admission or after treatment with granulocyte-colony stimulating factor (G-CSF). Most patients have absolute neutrophil counts (ANC) of less than 200/[mm.sup.3]. Other features in the peripheral blood include mild anemia, thrombocytosis, monocytosis and eosinophilia. Increased serum immunoglobulin levels, especially Ig G, were reported in a group of patients from Iran [5]. Bone marrow of patients with SCN characteristically reveals a "maturation arrest" at the promyelocyte/myelocyte stage. As in the peripheral blood, monocytosis and eosinophilia may also be present in the bone marrow. Molecular studies concerning the etiology of SCN revealed mutations in a few genetic loci (Table 2).

Cyclic Neutropenia

Cyclic neutropenia (CyN) refers to an autosomal dominant disorder with characteristic oscillations in neutrophils in approximately 21 days [1]. The disease was defined in 1910 in an infant who had recurrent fever, furunculosis, and severe neutropenia [6]. During the nadir of ANC (<500/[mm.sup.3]) for 3-5 days, aphthous stomatitis, periodontitis and other pyogenic infections may take place. There are also detectable oscillations in reticulocytes and platelets and sometimes of eosinophils and lymphocytes from normal to high levels during neutropenia. In contrast to SCN, no tendency to malignancy has been defined in patients with CyN.

Mutations related to perturbation of intracellular trafficking of elastase

The first attributed locus was the elastase (ELA2) gene. After studies showing a relationship between ELA2 mutations and CyN, the same relationship with SCN was first shown in 2000 [7]. In contrast with the first description as a "recessive disease" by Kostmann, germ-line dominant inheritance of ELA2 mutations was shown for both SCN and CyN patients. In vivo evidence supporting germ-line dominant inheritance in a report revealed five SCN cases with the same ELA2 mutation born to four mothers whose ELA2 genes were all wild-type. The mothers were impregnated by same-donor sperm obtained from a sperm bank, suggesting inheritance of mutation from the father [8]. Studies concerning the role of elastase in the pathophysiology revealed that myeloid precursors having mutated elastase are damaged in the early stages of myeloid differentiation; therefore, no mature myeloid cells develop in the bone marrow and peripheral blood of these patients. The father of a SCN patient who was mosaic for ELA2 mutation is another in vivo evidence [9]. Peripheral blood analysis showed that he had mutated and wild type ELA2 genes in T lymphocytes; however, there was no neutrophil bearing mutated gene, indicating that the neutrophils with mutated gene were eliminated during myeloid maturation. The authors suggested this finding as the first in vivo confirmation of the pathogenic nature of ELA2 mutations in humans. Mutation of the ELA2 gene is the most frequent molecular marker in patients with SCN, accounting for nearly half of all patients [10]. However, this mutation was not present in patients with the autosomal recessive form of SCN (Kostmann syndrome), supporting the existence of different inheritance patterns.

Neutrophil elastase, a serine protease, is normally located within azurophil granules of neutrophils and degrades Gramnegative bacteria and some other proteins such as coagulation proteins, growth factors, extracellular matrix proteins, immunoglobulins, and complement proteins, as well as PML-RAR[alpha] fusion protein [11]. Although a relationship between ELA2 mutations and SCN has been shown, mice deficient in elastase had normal granulopoiesis, suggesting that these mutations cause a gain rather than a loss of function [12]. However, these mice were more susceptible to Gram-negative bacterial sepsis and death but not to Gram-positive bacteria.

Mutations in the ELA2 gene result in disruption of elastase procession, preventing its transport to azurophil granules. The pathophysiological mechanism caused by ELA2 mutations has been explained in two ways. The first explanation [13] is based on evidence that the carboxy tail of elastase should be processed for its transport by adaptor protein 3 (AP3) to azurophil granules. Mutations in the ELA2 gene in SCN patients usually affect the carboxy terminal of elastase where it binds to AP3 [7]. Mutations in the binding site of AP3 also cause CN in patients with Hermansky-Pudlak syndrome type 2 (HPS2) [14]. There have been only four patients from three families diagnosed with HPS2. This syndrome, with typical findings including hypopigmentation and neutropenia, is equivalent to that found in three different species: gray collies, ruby drosophila and pearl mice [13]. In the case of SCN or HPS2, it is suggested that mutations disrupting the AP3 recognition signal cause overexpression of elastase erroneously localized in the plasma membrane. Another factor for increased overexpression of elastase is mutations in the transcriptional repressor of that ELA2 gene, Gfi1, that lead to accumulation of elastase in the plasma membrane due to overproduction [15]. Gfi1 normally represses the expression of many other genes as well as of ELA2 [16]. Taken together, in this explanation, the authors suggest that overexpression of elastase in the plasma membrane is caused by "excessive routing of neutrophil elastase to the plasma membrane" due to mutations in ELA2, AP3 or Gfi1 genes. This overexpression occurring in myeloid precursors may cause loss of these cells, which results in the "maturation arrest" observed in the bone marrow of SCN patients.

The second explanation of the pathogenesis of SCN suggests that ELA2 mutations lead to accumulation of elastase within the cytoplasm, not in the membrane, of myeloid precursors [17]. The investigators used an inducible cell culture-based system to express a panel of ELA2 mutations and found that there was a disruption of intracellular elastase processing at different levels due to different mutations, as suggested in the above-mentioned studies. However, immunofluorescence studies revealed that the mutant elastase was localized within cytoplasm, and co-localized with calnexin, a marker of endoplasmic reticulum (ER). Furthermore, an identical pattern of elastase accumulation has also been shown through analysis of granulocytes from patients with SCN. Finally, the authors showed increased apoptosis in cells expressing mutant elastase associated with findings of "unfolded protein response" (UPR). In normal circumstances, neutrophil elastase is folded within ER like many other proteins. Accumulation of unfolded mutant elastase in ER triggers UPR, a coordinated adaptive response in order to relieve stress in ER [18]. The aim of this reaction is to reduce misfolded proteins within the ER. During this task, three transmembrane ER proteins, PKR-like ER kinase (PERK, activating transcription factor 6 (ATF6), and inositol requiring enzyme 1(IRE1), regulate three main reactions to reduce misfolded proteins. Under normal circumstances, these three transmembrane ER proteins are associated with an ER chaperone protein, Bip/GRP78, that maintains them in an inactive state. During ER stress caused by misfolded proteins, Bip/GRP78 preferentially associates with misfolded proteins, a reaction that finally unbinds transmembrane ER proteins. If the ER stress is severe and these proteins are inadequate to reduce the stress, UPR triggers apoptosis [19]. Therefore, the authors suggested that mutant elastase within ER (in the cytoplasm) causes UPR and finally apoptosis of early myeloid cells.

Why mutations at the same genetic locus cause two different clinical pictures, SCN and CyN, is not yet clear. One explanation is that the mutations in the ELA2 gene occupy different sites in patients with CyN and SCN. It has been reported that in CyN, mutations usually affect one of three different positions in intron 4 [20]. They disrupt the normal splice donor site at the end of the 4th exon, causing use of a cryptic, upstream splice acceptor site. That results in the internal inframe deletion causing synthesis of a stumpy protein. However, in patients with SCN, chain-terminating mutations are prevalent and intron 4 mutations are very rare. The molecular pathophysiology of CyN is not well understood. The defect is in the stem cell, as it was observed in an in vivo example. A report of a patient with leukemia in relapse who was transplanted from her HILA-identical sibling suffering from CyN resulted in the same oscillations in neutrophils in the recipient [21]. It was hypothesized that if the normal inhibitory feedback from neutrophils to regulate myelopoiesis is in extreme inhibition, myeloid maturation stops and neutropenia occurs. But this suppression is a temporary event that leads to subsequent myelopoietic activity [22]. A neutrophil membrane extract, CAMAL (common antigen of myelogenous leukemia), has been shown to have this inhibitory property [23]. Elastase is an active component of CAMAL, supporting a role for mutant elastase in the extreme inhibition of myelopoiesis observed in CyN [24].

Mutations related to mitochondrial membrane stability

Since ELA2 mutations are responsible for approximately half of the patients with SCN and at least two forms of inheritance have been described by clinical studies, recent research has been focused on finding new mutations that cause this phenotype. In the search of a gene responsible for the recessive inheritance observed in 20 Middle Eastern children mostly from Turkey and three Swedish children from the original Kostmann family, a new genetic locus at chromosome 1 821.3, HAX1, was linked to SCN [25]. The HAX1 gene protein product is involved in stabilizing the mitochondrial membrane potential [26]. HAX1-deficient neutrophils have revealed increased spontaneous and tumor necrosis factor (TNF)a- or H202-induced apoptosis [25]. Reconstitution of the cellular phenotype of HAX1-deficient cells by retroviral wild-type gene transfer resulted in a decrease in the rate of apoptosis in cell cultures. Since HAX1 is a ubiquitously expressed gene, the authors searched non-hematopoietic cells for apoptosis in HAX1-deficient patients. Interestingly, fibroblasts from patients showed a more rapid loss of their membrane potential after exposure to valinomycin compared to those from healthy donors. Their conclusion on the basis of myeloid-specific apoptosis was that this effect might be due to intrinsic differences in the molecular control of apoptosis in neutrophils compared with other cell types. HAX1 mutation is responsible for approximately 30% of SCN cases. Molecular analysis showed that the same mutation in the HAX1 gene was present in patients from Turkey, Iran and Lebanon (W44X). Splenomegaly was a prominent clinical feature in these patients. However, the Kostmann family members had a different mutation (Q1 90X) in the HAX1 gene. None of these patients had ELA2 mutation.

Mutations related to transcriptional activation

Recently, lymphoid enhancer-binding factor (LEF-1) has been shown to play a key leading role in the regulation of proliferation and differentiation of myeloid cells [27]. It acts as an architectural transcription factor that regulates expression of many genes, including ELA2, by bending helical phasing of transcription binding sites [28]. Compared to healthy controls, LEF-1 mRNA expression was low in promyelocytes derived from SCN patients. It has been shown that LEF-1 is a transcriptional activator of both the ELA2 gene and the C/EBPa gene, which is also a transcriptional activator of the ELA2 gene. Analysis of CD33+ bone marrow cells from patients with SCN showed significant decrease in mRNA levels of LEF-1 and its target genes cyclin D1, c-myc, survivin C/EBPa, and ELA2, those involved in survival, proliferation and differentiation (Figure 1). Importantly, reconstitution of LEF-1 in early hematopoietic progenitors corrected the defective myelopoiesis in two individuals with SCN. It has been suggested that LEF-1 is a decisive factor for the regulation of myelopoiesis and its absence plays a critical role in the defective myeloid maturation in individuals with CN.

Malignant transformation and G-CSF receptor mutations

In SCN patients, cumulative incidence of leukemia has been reported as 21 % after 10 years [29]. Incidence of leukemia is elevated in patients who need higher (more than 8 [micro]g/ kg) doses of G-CSF (40%) compared to those who need lower doses (11%). Leukemic transformation occurred in patients with both ELA2 and HAX1 mutations [30,31]. Patients with RAS and G-CSF receptor (G-CSFR) gene mutations, monosomy 7, and Down syndrome are at high risk of developing leukemia. Recently, abnormal sensitivity and clonal expansion of cells with monosomy 7 in response to G-CSF has been reported [32].

Mutations in the G-CSFR gene are deemed to be acquired since they have not been detected at birth in any patient with SCN. This mutation has been found only in patients with SCN, and not in any other form of CN. Incidence of G-CSFR mutations is remarkably high in SCN patients who developed leukemia (80%) compared to those without leukemia (30%), which suggests a role for this gene in leukemogenesis [33]. Interestingly, the loss of mutated clone after cessation and regrowth after reinduction of G-CSF treatment has been reported. Mutations mostly result in a truncated G-CSFR protein that activates STAT5, a signaling protein known to be involved in leukemogenesis [34].

Congenital neutropenia due to defective RNA processing


Shwachman Diamond syndrome

Shwachman Diamond syndrome (SDS) is an autosomal recessive disorder that mainly affects two organs, the bone marrow and pancreas, with a strong propensity to malignancy. It was described by Shwachman and Diamond [35] in 1964 and subsequently by Bodian et al. [36]; thus, Shwachman Bodian Diamond syndrome (SBDS) is a synonym for this syndrome. Clinical manifestations begin from early infancy, including failure to thrive and steatorrhea due to exocrine pancreatic insufficiency; however, steatorrhea may resolve in half of the patients with ageing [37]. Serum isoamylase level is low at all ages and trypsinogen level is low below the age of three years. Pathologic and imaging studies show fatty replacement of pancreatic tissue. Elevated liver enzymes may accompany the clinical picture frequently during the first two years, after which, as with steatorrhea, they normalize with age. Neutropenia (ANC <1500/[mm.sup.3]) is found in the majority of patients, being intermittent in two-thirds and chronic in the remainder. Furthermore, neutrophil chemotaxis was found to be decreased [38]. Anemia, thrombocytopenia, pancytopenia, and elevated hemoglobin F levels may also be associated with neutropenia. Bone marrow cytology is usually not pathognomonic. On the other hand, baseline dysplasia in all three hematopoietic lineages, which should be distinguished from myelodysplastic syndrome, can be present. Although the clinical significance is not clear, clonal cytogenetic abnormalities, mostly in chromosome 7, are common in patients with SIDS [39]. Acute myeloblastic leukemia/myelodysplastic syndrome with complex clonal cytogenetics and poor prognosis frequently develops in these patients. Median age at diagnosis of malignancy is 19 years [40]. Growth retardation, metaphyseal dysostosis most commonly affecting the femoral head, and some endocrine disorders such as type 2 diabetes mellitus, growth hormone deficiency, and hypothyroidism are some other features of SIDS.

SBDS gene mutations

Molecular analysis showed that SIDS is caused by mutations in the SBDS gene on chromosome 7g11. A pseudogene, SBDSP, occupies a locally duplicated genomic segment at the distal part of chromosome 7 and shares 97% nucleotide identity with SBDS [41]. Conversion mutations due to recombination of SBDS with SBDSP resulting in unidirectional gene conversion from the pseudogene to SBDS have been shown to be responsible for disease (Figure 2). It was revealed that converted segments were restricted to a short fragment extending approximately 240 by in exon 2 and consistently included at least one of two pseudogene-like sequence changes that result in protein truncation. However, a Japanese study showed that conversion mutations, either homozygous or compound heterozygous, may take place at exons 1 and 3 as well as exon 2 [42].

SDBS protein is a member of a highly conserved protein family of unknown function with putative orthologs in dissimilar species such as plants, yeast, and vertebrate animals, located within highly conserved operons [43]. These are homologs of RNA-processing genes, suggesting that SIDS may be caused by a deficiency in an aspect of RNA metabolism [44]. An elegant study done in SDBS gene knockdown zebra fish showed a morphogenetic defect in the pancreas that alters the spatial relationship between exocrine and endocrine components, and also defective granulopoiesis, resembling patients with SIDS [45]. This study also showed that SIDS protein is expressed throughout embryogenesis.

Cartilage hair hypoplasia/metaphyseal chondrodysplasia

Cartilage hair hypoplasia (CHH) or metaphyseal chondrodysplasia was first described among Old Order Amish by McKusick et al. [46] in 1965 as an autosomal recessive disease. Characteristic features include short-limbed short stature, metaphyseal chondrodysplasia of the tubular bones, hypoplastic hair, cellular immune deficiency, macrocytic anemia that spontaneously recovers before adulthood, and moderate to severe neutropenia (ANC: 100-2000/[mm.sup.3]) [47]. The patients suffer from recurrent severe infections, particularly varicella zoster due to neutropenia and cellular immune deficiency [48].

RMRP mutations in CHH and related disorders

In eukaryotes, approximately 80% of the RNA is in the form of ribosomal RNA (rRNA). There are four kinds of rRNA (5S, 5.8S, 18S, and 28S), and each represents as one copy per ribosome [49]. Three of them (5.8S, 18S, and 28S) are made by chemical modification and cleavage of a large precursor rRNA. Modification is made at specific positions guided by special RNAs termed as "guide RNA' or "SnoRNA" (small nucleolar RNA).


Recently, mutations in RNAse mitochondrial RNA processing RNA (RMRP), a noncoding SnoRNA that functions itself without being translated into a protein, have been connected to disorders mostly exhibiting skeletal dysplasia. These disorders include metaphyseal dysplasia without hypotrichosis (MDWH), anauxetic dysplasia (AD), kyphomelic dysplasia (KD) and Omenn syndrome, as well as CHH (Figure 3) [50]. Some other gene mutations in rRNA processing other than RMRP have been shown to result in disorders with bone marrow involvement such as dyskeratosis congenita caused by DKC1 mutations affecting rRNA modification, and Diamond-Blackfan anemia caused by RPS19 affecting 40S ribosomal subunit maturation. It is interesting that there is accumulating evidence showing a connection between rRNA processing defects and disorders affecting bone and bone marrow.

At least three functions have been attributed to RMRP: processing of mitochondrial RNA that functions as a primer for mitochondrial DNA replication in mitochondria, endonucleotic cleavage of precursor 5.8S rRNA and processing of CLB2 mRNA that normally disappears rapidly as cells complete mitosis [51]. Despite being very similar to CHH, patients with MDWH (MIM#, 250460) do not have hair defect or immune deficiency. Patients with AD (MIM#, 607095) have extremely short stature, hypodontia, and mild mental retardation, but do not have tendency to cancer. Comparison of phenotype scores and rRNA and mRNA cleavage activities disclosed significant negative correlations between the degree of bone dysplasia and rRNA cleavage activity, between the degree of immunodeficiency or hematological abnormalities and mRNA cleavage activity, and between the incidence of hair hypoplasia and mRNA cleavage activity [52]. These findings may explain genotype/phenotype differences among patients with CHH, MDWH, and AD. Mutations that lead to CHH mostly originated from the transcribed region and the promoter region. The founder mutation in CHH is a 70A>G point mutation that affects both rRNA and mRNA processing, whereas mutations resulting in AD affected ribosomal construction but not CLB2 mRNA levels [53,54]. In CHH, defect in processing CLB2 mRNA results in inability to exit from mitosis and therefore malignancy.


In conclusion, the recent advances in molecular medicine have led to new insights into the congenital neutropenias. Therefore, the invention of underlying molecular defects defined by means of these disorders is very important, not only for understanding the pathogenesis causing these disorders but also for understanding some unknown molecular mechanisms.

Received August 2, 2008 Accepted September 10, 2008

Gelis tarihi: 02 Agustos 2008 Kabul tarihi: 10 Eylul 2008


[1.] Shende A. Disorders of white blood cells. In: Lanzkowsky P, editor. Manual of Pediatric Hematology and Oncology. 4th ed. California: Elsevier, 2005:209-49.

[2.] Kostmann R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl 1956;45(Suppl 105):178.

[3.] Dinauer MC. The phagocyte system and disorders of granulopoiesis and granulocyte function. In: Nathan DG, Orkin SH, Ginsburg D, Look AT, editors. Nathan and Oski's Hematology of Infancy and Childhood. 6th ed. Philadelphia: Saunders, 2003:923-1010.

[4.] Zeidler C. Congenital neutropenias. Hematology 2005;10 (Suppl 1):306-11.

[5.] Rezaei N, Moin M, PourpakZ, RamyarA, Izadyar M, Chavoshzadeh Z, Sherkat R, Aghamohammadi A, Yeganeh M, Mahmoudi M, Mahjoub F Germeshausen M, Grudzien M, Horwitz MS, Klein C, Farhoudi A. The clinical, immunohematological, and molecular study of Iranian patients with severe congenital neutropenia. J Clin Immunol 2007;27:525-33.

[6.] Leale M. Recurrent furunculosis in an infant showing an unusual blood picture. JAMA 1910;54:1854-5.

[7.] Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, Boxer LA, Kannourakis G, Zeidler C, Welte K, Benson KF, Horwitz M. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000;96:2317-22.

[8.] Boxer LA, Stein S, Buckley D, Bolyard AA, Dale DC. Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations. J Pediatr 2006;148:633-6.

[9.] Ancliff PJ, Gale RE, Watts MJ, Liesner R, Hann IM, Strobel S, Linch DC. Paternal mosaicism proves the pathogenic nature of mutations in neutrophil elastase in severe congenital neutropenia. Blood 2002;100:707-9.

[10.] Bellanne-Chantelot C, Clauin S, Leblanc T, Cassinat B, RodriguesLima F, Beaufils S, Vaury C, Barkaoui M, Fenneteau O, MaierRedelsperger M, Chomienne C, Donadieu J. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood 2004; 103:4119-25.

[11.] Lane AA, Ley TJ. Neutrophil elastase cleaves PML-RAR-alpha and is important for the development of acute promyelocytic leukemia in mice. Cell 2003;115:305-18.

[12.] Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, Shapiro SD. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 1998;4:615-8.

[13.] Horwitz M, Benson KF, Duan Z, Li FQ, Person RE. Hereditary neutropenia: dogs explain human neutrophil elastase mutations. Trends Mol Med 2004;10:163-70.

[14.] Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell 1999;3:11-21.

[15.] Person RE, Li FQ, Duan Z, Benson KF Wechsler J, Papadaki HA, Eliopoulos G, Kaufman C, Bertolone SJ, Nakamoto B, Papayannopoulou T, Grimes HL, Horwitz M. Mutations in proto oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet 2003;34:308-12.

[16.] Duan Z, Horwitz M. Targets of the transcriptional repressor oncoprotein Gfi-1. Proc Natl Acad Sci U S A 2003;100:5932-7.

[17.] Kollner I, Sodeik B, Schreek S, Heyn H, von Neuhoff N, Germeshausen M, Zeidler C, Kruger M, Schlegelberger B, Welte K, Beger C. Mutations in neutrophil elastase causing congenital neutropenia lead to cytoplasmic protein accumulation and induction of the unfolded protein response. Blood 2006;108:493-500.

[18.] Xia J, Link DC. Severe congenital neutropenia and the unfolded protein response. Curr Opin Hematol 2008;15:1-7.

[19.] Ron D, Walter P Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29.

[20.] Horwitz M, Benson KF, Person RE, Aprikyan AG, Dale DC. Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet 1999;23:433-6.

[21.] Krance RA, Spruce WE, Forman SJ, Rosen RB, Hecht T, Hammond WP, Blume KG. Human cyclic neutropenia transferred by allogeneic bone marrow grafting. Blood 1982;60:1263-6.

[22.] Horwitz MS, Duan Z, Korkmaz B, Lee HH, Mealiffe ME, Salipante SJ. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 2007;109:1817-24.

[23.] Leitch HA, Levy JG. Reversal of CAMAL mediated alterations of normal and leukemic in vitro myelopoiesis using inhibitors of proteolytic activity. Leukemia 1994;8:605-11.

[24.] El Ouriaghli F, Fujiwara H, Melenhorst JJ, Sconocchia G, Hensel N, Barrett AJ. Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood 2003;101:1752-8.

[25.] Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schaffer AA, Rathinam C, Boztug K, Schwinzer B, Rezaei N, Bohn G, Melin M, Carlsson G, Fadeel B, Dahl N, Palmblad J, Henter JI, Zeidler C, Grimbacher B, Welte K. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007;39:86-92.

[26.] Suzuki Y, Demoliere C, Kitamura D, Takeshita H, Deuschle U, Watanabe T. HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases. J Immunol 1997;158:2736-44.

[27.] Skokowa J, Cario G, Uenalan M, Schambach A, Germeshausen M, Battmer K, Zeidler C, Lehmann U, Eder M, Baum C, Grosschedl R, Stanulla M, Scherr M, Welte K. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 2006;12:1191-7.

[28.] Love JJ, Li X, Case DA, Giese K, Grosschedl R, Wright PE. Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 1995;376:791-5.

[29.] Rosenberg PS, Alter BP, Bolyard AA Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC; Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe CN receiving long-term G-CSF therapy. Blood 2006;107:4628-35.

[30.] Bellannb-Chantelot C, Clauin S, Leblanc T, Cassinat B, Rodrigues-Lima F, Beaufils S, Vaury C, Barkaoui M, Fenneteau O, Maier-Redelsperger M, Chomienne C, Donadieu J. Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood 2004; 103:4119-25.

[31.] Germeshausen M, Grudzien M, Zeidler C, Abdollahpour H, Yetgin S, Rezaei N, Ballmaier M, Grimbacher B, Welte K, Klein C. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood 2008;111:4954-7.

[32.] Sloand EM, Yong AS, Ramkissoon S, Solomou E, Bruno TC, Kim S, Fuhrer M, Kajigaya S, Barrett AJ, Young NS. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A 2006;103:14483-8.

[33.] Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey. Blood 2007;109:93-9.

[34.] Liu F Kunter G, Krem MM, Eades WC, Cain JA, Tomasson MH, Hennighausen L, Link DC. Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin Invest 2008;118:946-55.

[35.] Shwachman H, Diamond LK, Oski FA, Khaw KT. The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr 1964;65:645-63.

[36.] Bodian M, Sheldon W, Lightwood R. Congenital hypoplasia of the exocrine pancreas. Acta Paediatr 1964;53:282-93.

[37.] Shimamura A. Shwachman-Diamond syndrome. Semin Hematol 2006;43:178-88.

[38.] Aggett PJ, Harries JT, Harvey BA, Soothill JF. An inherited defect of neutrophil mobility in Shwachman syndrome. J Pediatr 1979;94:391-4.

[39.] Dror Y, Durie P, Ginzberg H, Herman R, Banerjee A, Champange M, Shannon K, Malkin D, Freedman MH. Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study. Exp Hematol 2002;30:659-69.

[40.] Dror Y. Shwachman-Diamond syndrome. Pediatr Blood Cancer 2005;45:892-901.

[41.] Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, Rommens JM. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003;33:97-101.

[42.] Nakashima E, Mabuchi A, Makita Y, Masuno M, Ohashi H, Nishimura G, Ikegawa S. Novel SBDS mutations caused by gene conversion in Japanese patients with Shwachman-Diamond syndrome. Hum Genet 2004;114:345-8.

[43.] Shammas C, Menne TF, Hilcenko C, Michell SR, Goyenechea B, Boocock GR, Durie PR, Rommens JM, Warren AJ. Structural and mutational analysis of the SBDS protein family. Insight into the leukemia-associated Shwachman-Diamond syndrome. J Biol Chem 2005;280:19221-9.

[44.] Savchenko A, Krogan N, Cort JR, Evdokimova E, Lew JM, Yee AA, Sanchez-Pulido L, Andrade MA, Bochkarev A, Watson JD, Kennedy MA, Greenblatt J, Hughes T, Arrowsmith CH, Rommens JM, Edwards AM. The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism. J Biol Chem 2005;280:19213-20.

[45.] Venkatasubramani N, Mayer AN.A zebrafish model for the Shwachman-Diamond syndrome (SIDS). Pediatr Res 2008;63:348-52.

[46.] McKusick VA, Eldridge R, Hostetler JA, Ruangwit U, Egeland JA. Dwarfism in the Amish. II. Cartilage-hair hypoplasia. Bull Johns Hopkins Hosp 1965;116:285-326.

[47.] Makitie O, Sulisalo T, de la Chapelle A, Kaitila I. Cartilage-hair hypoplasia. J Med Genet 1995;32:39-43.

[48.] Lux SE, Johnston RB Jr, August CS, Say B, Penchaszadeh VB, Rosen FS, McKusick VA. Chronic neutropenia and abnormal cellular immunity in cartilage-hair hypoplasia. N Engl J Med 1970;282:231-6.

[49.] How cells read the genome from DNA to protein. In: Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, editors. Molecular Biology of the Cell. 5th ed. New York: Garland Science, 2002: 329-410.

[50.] Martin AN, Li Y. RNase MRP RNA and human genetic diseases. Cell Res 2007;17:219-26.

[51.] Cal T, Aulds J, Gill T, Cerio M, Schmitt ME. The Saccharomyces cerevisiae RNase mitochondrial RNA processing is critical for cell cycle progression at the end of mitosis. Genetics 2002;161:1029-42.

[52.] Thiel CT, Mortier G, Kaitila I, Reis A, Rauch A. Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum. Am J Hum Genet 2007;81:519-29.

[53.] Ridanp55 M, Sistonen P, Rockas S, Rimoin DL, M5kitie O, Kaitila I. Worldwide mutation spectrum in cartilage-hair hypoplasia: ancient founder origin of the major70A-G mutation of the untranslated RMRP Eur J Hum Genet 2002;10:439-47.

[54.] Thiel CT, Horn D, Zabel B, Ekici AB, Salinas K, Gebhart E, Ruschendorf F, Sticht H, Spranger J, Muller D, Zweier C, Schmitt ME, Reis A, Rauch A. Severely incapacitating mutations in patients with extreme short stature identify RNA processing endoribonuclease RMRP as an essential cell growth regulator. Am J Hum Genet 2005;77:795-806.

[55.] Devriendt K, Kim AS, Mathijs G, Frints SG, Schwartz M, Van Den Oord JJ, Verhoef GE, Boogaerts MA, Fryns JP, You D, Rosen MK, Vandenberghe P Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001;27:313-7.

[56.] Huizing M, Anikster Y, Gahl WA. Hermansky-Pudlak syndrome and Chediak-Higashi syndrome: disorders of vesicle formation and trafficking. Thromb Haemost 2001;86:233-45.

[57.] Chandler KE, Kidd A, AI-Gazali L, Kolehmainen J, Lehesjoki AE, Black GC, Clayton-Smith J. Diagnostic criteria, clinical characteristics, and natural history of Cohen syndrome. J Med Genet 2003;40:233-41.

[58.] Anikster Y, Huizing M, Anderson PD, Fitzpatrick DL, Klar A, Gross-Kieselstein E, Berkun Y, Shazberg G, Gahl WA, Hurvitz H. Evidence that Griscelli syndrome with neurological involvement is caused by mutations in RAB27A, not MYO5A. Am J Hum Genet 2002;71:407-14.

[59.] Schlame M, Ren M. Barth syndrome, a human disorder of cardiolipin metabolism. FEES Lett 2006;580:5450-5.

[60.] Buckley RH. Seminal article with commentaries: agammaglobulinemia. Pediatrics 1998;102:PS213-PS215.

[61.] Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, Lebbe C, Kerob D, Dupuy A, Hermine O, Nicolas JF, Latger-Cannard V, Bensoussan D, Bordigoni P, Baleux F, Le Deist F, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005;105:2449-57.

[62.] Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, Fanslow WC, Belmont J, Spriggs MK. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.

[63.] Ferrari S, Giliani S, Insalaco A, AI-Ghonaium A, Soresina AR, Loubser M, Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N, Durandy A, Tbakhi A, Notarangelo LID, Plebani A. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Nat Acad Sci 2001;98:12614-9.

[64.] Annabi B, Hiraiwa H, Mansfield BC, Lei KJ, Ubagai T, Polymeropoulos MH, Moses SW, Parvari R, Hershkovitz E, Mandel H, Fryman M, Chou JY The gene for glycogen-storage disease type 1b maps to chromosome 11823. Am J Hum Genet 1998;62:400-5.

Namyk Ozbek Department of Pediatric Hematology, Baskent University, Faculty of Medicine, Ankara, Turkey
Table 1. Common causes of congenital neutropenia

1. Severe congenital neutropenia

2. Cyclic neutropenia

3. Familial benign (ethnic) neutropenia

4. Cohen syndrome

5. Neutropenia associated with immune deficiency

a. Shwachman Diamond syndrome

b. Cartilage hair hypoplasia (chondrometaphyseal dysplasia)

c. Myelokathexis/WHIM (Warts, Hypogammaglobulinemia, Infections, and
 Myelokathexis) syndrome

d. X-linked agammaglobulinemia (Bruton's disease)

e. Hyper IgM syndrome

f. Reticular dysgenesis

g. Dubowitz syndrome

h. Cellular immune deficiency

6. Neutropenia associated with oculocutaneous albinism or lysosomal

a. Hermansky Pudlak syndrome Type 2

b. Chediak Higashi syndrome

c. Griscelli syndrome

7. Neutropenia associated with metabolic disorders

a. Glycogen storage disease Type 1b

b. Idiopathic hyperglycinemia

c. Organic (sovaleric, methyl malonic, propionic) acidemia

d. Barth syndrome

Table 2. Genetic mutations related to congenital neutropenia

Disorder MIM# Inheritance

 202700 AD

 608233 AR


 605998 AR

 138971 AR

 300299 X-R

Cyclic neutropenia 162800 AD

Chediak-Higashi 214500 AR

Cohen syndrome 216550 AR

Griscelli syndrome 607624 AR
Type 2

Shwachman-Diamond 260400 AR

Cartilage hair 250250 AR

Barth syndrome 302060 X-R

X-linked 300300 X-R

WHIM syndrome 193,670 AD (?)

Hyper IgM Type 1 308230 X-R

Hyper IgM Type 3 606843 AR

Glycogen storage 232220 AR
disease Type 1b

Disorder Chromosomal Gene

 19p13.3 ELA2

 5q14.1 AP3B1


 1q21.3 HAX1

 1p35-p34.3 CSF3R

 Xp11.23 WAS

Cyclic neutropenia 19p13.3 ELA2

Chediak-Higashi 1q42.1-q42.2 LYST

Cohen syndrome 8q22-q23 COH1

Griscelli syndrome 15q21 RAB27A
Type 2

Shwachman-Diamond 7q11 SBDS

Cartilage hair 9p21-p12 RMRP

Barth syndrome Xq28 TAZ

X-linked Xq21.3-q22 BTK

WHIM syndrome 2q21 CXCR4

Hyper IgM Type 1 Xq26 CD40Lgene

Hyper IgM Type 3 20q12-q13.2 CD40 gene

Glycogen storage 11q23 G6PT gene
disease Type 1b

Disorder Disorder


Cyclic neutropenia Cyclic neutropenia

Chediak-Higashi Chediak-Higashi
syndrome syndrome

Cohen syndrome Cohen syndrome

Griscelli syndrome Griscelli syndrome
Type 2 Type 2

Shwachman-Diamond Shwachman-Diamond
syndrome syndrome

Cartilage hair Cartilage hair
hypoplasia hypoplasia

Barth syndrome Barth syndrome

X-linked X-linked
agammaglobulinemia agammaglobulinemia

WHIM syndrome WHIM syndrome

Hyper IgM Type 1 Hyper IgM Type 1

Hyper IgM Type 3 Hyper IgM Type 3

Glycogen storage Glycogen storage
disease Type 1b disease Type 1b

Disorder Diagnostic Features and
 Mechanism of Disease

 Increased apoptosis of early
 granulocytes caused by defective
 transport of mutant
 elastase (see text)

 Hermansky-Pudlak syndrome
 Type 2; Increased apoptosis of
 early granulocytes caused by
 defective transport of
 elastase due to APB3
 mutations (see text)

SEVERE CONGENITAL Increased apoptosis of early
NEUTROPENIA granulocytes caused by
 increased elastase levels
 due to defect in
 transcriptional repression
 of ELA2 gene by Gfi1 (see text)

 Increased apoptosis due to
 impaired mitochondrial
 membrane stability
 (see text)

 Acquired mutation; Activation
 of STAT5 due to truncation
 of G-CSFR may cause leukemic
 transformation (see text)

 Neutropenic variant of
 Wiskott-Aldrich syndrome (WAS)
 [55]; Decreases the stability
 of the autoinhibited structure
 of WAS protein, resulting in
 activation of actin; Increased
 numbers of CD3+/CD8+/ CD57+ T
 lymphocytes may mediate

Cyclic neutropenia Excessive inhibition
 of myelopoiesis due to
 mutant elastase (see text)

Chediak-Higashi Partial albinism, giant
syndrome lysosomes in peripheral
 blood cells, impaired
 platelet function;
 Caused by mutation in
 the lysosomal
 trafficking regulator
 gene LYST [56];
 Tendency to malignancy

Cohen syndrome Mental retardation,
 microcephaly, characteristic
 facial features, childhood
 hypotonia and joint laxity, a
 cheerful disposition, and
 intermittent isolated neutropenia
 [57]; Disturbance in
 intracellular vesicle sorting
 and protein transport

Griscelli syndrome Partial albinism, frequent
Type 2 pyogenic infections, and acute
 episodes of fever, neutropenia,
 and thrombocytopenia [58]

Shwachman-Diamond Defective RNA processing
syndrome (see text)

Cartilage hair Defective RNA processing
hypoplasia (see text)

Barth syndrome Dilated cardiomyopathy, skeletal
 myopathy, abnormal mitochondria,
 and neutropenia; Inhibition of
 acyl-specific remodelling of
 cardiolipin results in changes
 in mitochondrial architecture
 and function [59]

X-linked Bruton disease; Decreased neutrophil
agammaglobulinemia numbers when rapid production is
 needed; Due to mutation in BTK
 (Bruton tyrosine kinase) gene,
 one of the genes responsible
 for myelopoiesis [60]

WHIM syndrome Warts, Hypogammaglobulinemia,
 tendency to Infections, and
 Myelokathexis that presents as
 neutrophils with cytoplasmic
 vacuoles and hypersegmented
 nuclei with dense, pyknotic lobes
 connected by long filaments; Caused
 by truncating mutations in the
 cytoplasmic tail domain of the
 gene encoding chemokine
 receptor-4 [61]

Hyper IgM Type 1 High IgM levels with absence of
 IgG, IgA, and IgE, resulting in a
Hyper IgM Type 3 profound susceptibility to bacterial
 and opportunistic infections,
 increased frequency of
 autoimmune neutropenia; Caused
 by defects in either CD40 or
 CD40L (ligand) [62,63]

Glycogen storage Recurrent infections, neutropenia,
disease Type 1b chronic inflammatory bowel disease
 that resolves with G-CSF treatment;
 Neutrophils are also defective in
 both motility and respiratory burst
 functions [64]
COPYRIGHT 2008 Aves Yayincilik
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Ozbek, Namyk
Publication:Turkish Journal of Hematology
Article Type:Report
Geographic Code:7TURK
Date:Mar 1, 2008
Previous Article:A rare presentation of multiple myeloma: Tc-99m MIBI SPECT imaging of orbital involvement/Multiple myeloma'nin nadir bir gorunumu: Orbital tutulumun...
Next Article:Transient depletion of innate immunity in varicella infections in otherwise healthy children/ Saglikli cocuklarda gelisen varisella enfeksiyonu...

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters